The University of Hong Kong
Hong Kong, 0000
NCT Number: NCT07037550
In the realm of dementia care, the imperative to intervene at the earliest stages of cognitive decline is paramount. Recognizing this pivotal moment, the development of innovative and effective interventions becomes imperative in delaying dementia progression.
Rooted in the Roy Adaptation Model and Zimmer's Theory of Psychological Empowerment, the investigator team has developed the empowerment-based dyadic strength-based intervention, which integrates strength-based and empowerment methodologies. Emphasizing a shift from deficits to capabilities, the strength-based approach fosters awareness of collective strengths within care dyads, facilitating coping mechanisms and resilience in the face of cognitive afflictions.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hong Kong, 0000
In the realm of dementia care, the imperative to intervene at the earliest stages of cognitive decline is paramount. Recognizing this pivotal moment, the development of innovative and effective interventions becomes imperative in delaying dementia progression.
Rooted in the Roy Adaptation Model and Zimmer's Theory of Psychological Empowerment, the investigator team has developed the empowerment-based dyadic strength-based intervention, which integrates strength-based and empowerment methodologies. Emphasizing a shift from deficits to capabilities, the strength-based approach fosters awareness of collective strengths within care dyads, facilitating coping mechanisms and resilience in the face of cognitive afflictions.
The objective of this study is:
After obtained the consent baseline data collection will be done. The participants will be randomized to receive either the ambassador-led strength-based intervention of usual care group. The post-test data collection will take place upon the completion of the program (9th week) and at 3-month thereafter.
The Strength-based intervention incorporates 8-week Ambassador-led strength-based intervention including:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Strength-based intervention incorporates 8-week Ambassador-led strength-based intervention including:
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the global cognition sore by the Alzheimer's Disease Assessment Scale -Cognitive Subscale (ADAS-Cog), the digit span-forward and backward test for attention and working memory, the list learning delayed recall test for episodic memory, 5-min Montreal Cognitive Assessment and Trail-Making Test for complex attention, executive function and task switching. The higher score indicates poor cognitive function
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the perceived self-efficacy in caregiving, to measure the caregivers' perceived self-efficacy in handling the symptoms of the persons with mild cognitive impairment and to control their own emotions. It scale from 0-100 with a higher score indicating a higher caregiving self-efficacy.
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the health-related quality of life (HRQL) covering physical, functional, psychosocial, interpersonal, and environmental status of the patient with dementia, scales 13 to 52, with higher score indicating better HRQL
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the changes in participant's mood status. The response set is a 4-point Likert scale, scale from 0-30, with a higher score indicating a higher level of depression.
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the quality of interpersonal relationships in the caregiving dyad, in the care recipient perspective. It measures aspects such as communication, support, and satisfaction within the dyad, providing insight into the dynamics of caregiving relationships in dementia care settings. It scale from 0-30 with a higher score indicating a better dyadic relationship.
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the quality of interpersonal relationships in the caregiving dyad, in the caregiver perspective. It measures aspects such as communication, support, and satisfaction within the dyad, providing insight into the dynamics of caregiving relationships in dementia care settings. It scale from 0-33 with a higher score indicating a better dyadic relationship.
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the neuro-psychiatric symptoms of the patient with dementia reported by the caregiver, scales from 12 to 96 with higher scores indicating higher severity
Time frame: baseline (T0), 9-weeks immediate posttest (T1), 3 months after the posttest (T2)
evaluate the behavioral changes associated with cognitive decline for those with mild cognitive impairment, which enables patients to self-report symptoms, aiding in early detection and intervention for mild behavioral impairment, a potential precursor to dementia. It scale from 0-102 with a higher score indicating a higher risk of behavioral changes associated with cognitive decline.
The University of Hong Kong
Other
Effectiveness of Strength-based Intervention for Elders With Dementia Living in the Community and Residential Units: a Randomized Controlled Trial
Acronym: STRENGTH-B
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07602283
Alzheimer Disease, Anxiety Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07630688
Alzheimer Disease, Behavior
Antalya, Muratpaşa, Turkey (Türkiye)
View Trial DetailsNCT06940687
Alzheimer Disease, Anxiety Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07651085
Alzheimer Disease, Basal Ganglia Diseases
Rome, Italy
View Trial Details